To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

NCT06378242 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

High-risk Non-muscle Invasive Bladder Cancer

Interventions

DRUG: Disitamab Vedotin for injection

Sponsor

RemeGen Co., Ltd.